A leading endocrinologist with the Food and Drug Administration recommended pursuing approval for puberty blockers for youth with gender dysphoria despite acknowledging that they raised the risk of depression and suicidality, according to internal emails.
Shannon Sullivan, the clinical team leader at the FDA’s Division of General Endocrinology, recommended to her supervisor in January 2022 that the agency approve puberty blockers to treat adolescents with gender dysphoria following a safety review that showed negative mental health results.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.